Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668483 | 0.88 | TSHR (0.36) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL6043806 | 0.86 | TDP1 (0.50) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL10878082 | 0.82 | TSHR (0.41) | TSHRTDP1PGDCYP2C9PDE4A | |
| SCHEMBL17323230 | 0.80 | SLC1A1 (0.43) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL5495547 | 0.80 | TDP1 (0.64) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL6670672 | 0.79 | MGAM (0.43) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL21427132 | 0.78 | TDP1 (0.42) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL6668479 | 0.77 | SLC1A1 (0.43) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL17323255 | 0.77 | MAPT (0.39) | TSHRTDP1HSD17B10MGAMGAA | |
| SCHEMBL17468524 | 0.77 | MAPT (0.39) | TSHRTDP1HSD17B10MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12285034-B2 | Human and non-human animal use of microbial anaplerotic oil | HELIAE DEVELOPMENT, LLC (US) | 2025-04-29 | — | — | US | disclosed |
| US-20230397642-A1 | HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OIL | HELIAE DEVELOPMENT, LLC | 2023-12-14 | — | — | US | disclosed |
| US-11758934-B2 | Human and non-human animal use of microbial anaplerotic oil | HELIAE DEVELOPMENT, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220400723-A1 | HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OIL | HELIAE DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-20220396814-A1 | Anaplerotic Oil Production In Microbials | HELIAE DEVELOPMENT, LLC | 2022-12-15 | — | — | US | disclosed |
| US-11457655-B2 | Human and non-human animal use of microbial anaplerotic oil | HELIAE DEVELOPMENT, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-11447803-B2 | Anaplerotic oil production in microbials | HELIAE DEVELOPMENT, LLC (US) | 2022-09-20 | — | — | US | disclosed |
| US-11434511-B2 | Anaplerotic oil production in microbials | HELIAE DEVELOPMENT, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3897185-A1 | HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OIL | Heliae Development LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210251270-A1 | HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OIL | HELIAE DEVELOPMENT, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20130072428-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120142590-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
| US-20100184643-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2008024858-A2 | METHODS AND COMPOUNDS REGULATING THE ERYTHROID RESPONSE TO IRON DEFICIENCY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-02-28 | — | — | WO | disclosed |
| CN-1920040-A | Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production | BASF AG (DE) | 2007-02-28 | — | — | CN | disclosed |
| CN-1807634-A | Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production | BASF AG (DE) | 2006-07-26 | — | — | CN | disclosed |
| EP-1334180-A4 | ISOCITRATE DEHYDROGENASE, GENE THEREOF, AND USE OF THE SAME IN THE TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND FATTY LIVER IN LIPID BIOSYNTHESIS | TG BIOTECH INC (KR) | 2005-04-06 | — | — | EP | disclosed |
| US-20040214270-A1 | Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fattly liver in lipid biosynthesis | TG BIOTECH, INC. (KR) | 2004-10-28 | — | — | US | disclosed |
| EP-1334180-A1 | ISOCITRATE DEHYDROGENASE, GENE THEREOF, AND USE OF THE SAME IN THE TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND FATTY LIVER IN LIPID BIOSYNTHESIS | TG Biotech, Inc. (KR) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002033063-A1 | ISOCITRATE DEHYDROGENASE, GENE THEREOF, AND USE OF THE SAME IN THE TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND FATTY LIVER IN LIPID BIOSYNTHESIS | TG BIOTECH, INC. (KR) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142590-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | MCL1, FECH, MPL | TSHR 3244/4885TDP1 4776/4885HSD17B10 1965/4885 |
| US-20130072428-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | HIF1AN, IDH2, IDH3B | TSHR 4057/4885TDP1 4822/4885HSD17B10 1965/4885 |
| US-20100184643-A1 | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency | EPOR, MPL, MCL1 | TSHR 3511/4885TDP1 4797/4885HSD17B10 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.